Abstract: The present invention provides novel antibodies that recognize the extracellular domain of a human CLCP1 antigen; nucleic acids encoding the antibodies; vectors carrying the nucleic acids in an expressible manner; transformed cells containing the vectors; methods for producing the antibodies; diagnostic methods for cancer or prognosis of cancer, immunohistological or immunocytological assay methods, and kits for determining the expression level of CLCP1 in cells or tissues, all of which use the antibodies; pharmaceutical compositions comprising the antibodies; agents for treating or preventing CLCP1-expressing cancer; agents for inhibiting growth, migration, invasion, or metastasis of CLCP1-expressing cancer cells; immunostaining agents for staining CLCP1-expressing cancer cells; and agents for treating or preventing CLCP1-expressing tumor.

Abstract: It is an object of the present invention to provide a novel fluorescent protein and a novel chromoprotein. The present invention provides a novel fluorescent protein derived from Montipora sp., Acropora sp. and Lobophytum crassum, and a novel chromoprotein derived from Actinia equine.

Abstract: An object of the present invention is to provide a red or orange fluorescent protein, which is characterized in that the difference (stokes shift) between an excitation peak value (wavelength of maximum absorption) and a fluorescence peak value (wavelength of maximum fluorescence) is greatened, so that the maximum fluorescence can be obtained by the maximum excitation. The present invention provides a novel fluorescent protein monomerized by introducing a mutation into a florescent protein derived from Fungia sp., and a novel chromoprotein and fluorescent protein derived from Montipora. sp.

Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.

Abstract: It is an object of the present invention to provide a novel fluorescent protein and a novel chromoprotein. The present invention provides a novel fluorescent protein derived from Montipora sp., Acropora sp. and Lobophytum crassum, and a novel chromoprotein derived from Actinia equine.

Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.

Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.

Abstract: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.

Abstract: Presence of free insulin receptor ?-subunit in blood was discovered. Furthermore, methods for measuring the insulin receptor ?-subunit was provided, the method comprising the steps of contacting the insulin receptor ?-subunit in a blood sample with an antibody recognizing the insulin receptor ?-subunit, and detecting the binding between the two. Measurement of the free insulin receptor ?-subunit in the blood is useful for evaluating risk factors for diabetes. In addition, the measurement methods of the present invention showed that concentrations of the free insulin receptor ?-subunit in the blood of diabetes or cancer patients are significantly high. Free insulin receptor ?-subunit in blood is useful as a marker for diabetes or cancer.

Abstract: The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.

Abstract: It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from Anthopleura inornata, which have certain property, and fluorescent proteins from Trachyphyllia geoffroyi and Scolymia vitiensis, which have certain fluorescent property.

Abstract: Disclosed is an antibody having an enhanced ADCC activity. Also disclosed is a method for producing the antibody. It was attempted to advance the technique of the amino acid mutation in an Fc region established by researchers of Genentech Inc. or the like, and a study was made on whether or not the ADCC activity can be enhanced by the mutation of an amino acid residue in an Fc region into cysteine (Cys) which may cause a drastic structural change that cannot be drawn by a computational search. As a consequence, a chemeric antibody is provided which has the mutation of an amino acid residue at least one position selected from the group consisting of 286th, 287th, 288th, 289th, 290th, 291st, 292nd, 294th, 298th, 301st, 302nd, 303rd, 305th, 306th, 307th, 308th and 309th positions into a Cys residue in an H-chain constant region.

Abstract: Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.

Abstract: Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.

Abstract: Presence of free insulin receptor ?-subunit in blood was discovered. Furthermore, methods for measuring the insulin receptor ?-subunit was provided, the method comprising the steps of contacting the insulin receptor ?-subunit in a blood sample with an antibody recognizing the insulin receptor ?-subunit, and detecting the binding between the two. Measurement of the free insulin receptor ?-subunit in the blood is useful for evaluating risk factors for diabetes. In addition, the measurement methods of the present invention showed that concentrations of the free insulin receptor ?-subunit in the blood of diabetes or cancer patients are significantly high. Free insulin receptor ?-subunit in blood is useful as a marker for diabetes or cancer.

Abstract: Fusion partner cells that enable production of heterohybridomas even from cells of species other than mouse were produced by fusing myeloma cells derived from a first animal species with leukemia cells derived from a second animal species, which have an extra S phase in the cell cycle and have the property of diploidizing. Stable production of substances can be achieved by producing heterohybridomas through cell fusion between the fusion partner cells and substance-producing cells of an animal other than mouse.

Abstract: The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.

Abstract: An objective of the present invention is to provide methods for selecting candidate peptides presented on the surface of cancer cells following binding to MHC class I molecules, wherein the peptides are involved in the stimulation of T cell immunity (cellular immunity). The present inventors discovered a new principle of MHC I-mediated antigen presentation in which a T cell antigen epitope is more efficiently presented on MHC I molecules when it is positioned at the N-terminal side than when positioned at the C-terminal side.

Abstract: It is an object of the present invention to provide a novel fluorescent protein and a novel chromoprotein. The present invention provides a novel fluorescent protein derived from Montipora sp., Acropora sp. and Lobophytum crassum, and a novel chromoprotein derived from Actinia equine.

Abstract: The object of the present invention is to provide a novel fluorescent protein in which on and off of fluorescence thereof can be controlled by irradiation with lights of two different wavelengths. The present invention provides a fluorescent protein shown in the following (a) or (b); (a) a protein which has the amino acid sequence shown in SEQ ID NO: 3 or 7; or (b) a protein which has an amino acid sequence comprising a deletion, substitution, and/or addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 3 or 7, and which has fluorescence characteristics of exhibiting a photochromic effect.